FDA Guidance on Decision Support Software: Implications for Industry

by Epstein Becker & Green
Contact

Epstein Becker & Green

On December 8, 2017, the U.S. Food and Drug Administration (“FDA”) issued draft guidance titled “Clinical and Patient Decision Support Software” (“CDS Guidance”). According to FDA Commissioner Scott Gottlieb, M.D., the CDS Guidance is intended to clarify the types of clinical decision support software (“CDS”) that would no longer be defined as a medical device and, therefore, would not be regulated by the FDA.

Stakeholders in the digital health industry have long awaited clarification of the scope of the FDA’s regulatory oversight of CDS, specifically the differentiation between low-risk and high-risk CDS. The FDA had first announced its plan to develop guidance for CDS in 2011. Unfortunately, stakeholders seeking clarity may have to wait longer.

CDS Guidance Does Not Incorporate a Risk Framework

In 2014, the FDA was actively engaged with the International Medical Device Regulators Forum (“IMDRF”) in developing a risk framework, which can be summarized into two factors that drive risk:

  1. Significance of the information provided by the Software as a Medical Device (“SaMD”) to the health care decision—i.e., is the information critical to the decision-making, or more peripheral?
  2. State of the health care situation or condition—i.e., could the patient die, and how urgent is the condition?

Unfortunately, the FDA does not incorporate the IMDRF risk framework into the CDS Guidance. Rather, the FDA appears to merely restate the 21st Century Cures Act (“Cures Act”) framework that exempts software if a physician user can independently review the basis for the recommendation. The CDS Guidance suggests that software that does not provide a reasonable basis for reviewing a recommendation will always be regulated regardless of risk. For example, software that utilizes a complex machine learning algorithm to determine which patients have the common cold will be regulated because a physician is unable to mentally duplicate the algorithm.

The CDS Guidance does not answer basic questions when applied to current and future forms of CDS, which is and will be based on machine learning and other forms of complex algorithms that add to the knowledge of physicians. Unless the FDA intends to regulate all such software regardless of risk, the CDS Guidance does little to elaborate on the analysis used to differentiate the types of CDS to be regulated by the agency.

CDS Guidance Does Not Clearly Differentiate Between Regulated and Unregulated CDS

The CDS Guidance provides several examples of unregulated and regulated CDS; however, no explanation is given as to why a particular example triggers regulation or not. Most of the examples of unregulated software appear to make recommendations based on information that is already available to the user. Most of the examples of CDS and other software functions to be regulated as medical devices appear to utilize computer-based algorithms that analyze, manipulate, and/or extrapolate signals generated from medical devices.

Although the section on patient decision support software (“PDS”) states that the FDA intends to exempt certain software, the test largely relies on whether patients can understand the basis for the software. Considering that technological sophistication will vary across the patient population, this is not a clear standard. This would most likely set a very high bar for PDS and therefore subject most PDS to FDA regulation.

Conclusion

The draft CDS Guidance elaborates little more than what the Cures Act already set forth. This would leave an industry segment that is advancing at a rapid pace with much ambiguity as to the rules of the road. CDS producers and their investors, as well as consumer/patient advocates, may wish to press the FDA to make the final guidance much crisper. The public has until February 6, 2018, to comment.

Written by:

Epstein Becker & Green
Contact
more
less

Epstein Becker & Green on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.